TWI788094B - Contact lens and product thereof - Google Patents
Contact lens and product thereof Download PDFInfo
- Publication number
- TWI788094B TWI788094B TW110141914A TW110141914A TWI788094B TW I788094 B TWI788094 B TW I788094B TW 110141914 A TW110141914 A TW 110141914A TW 110141914 A TW110141914 A TW 110141914A TW I788094 B TWI788094 B TW I788094B
- Authority
- TW
- Taiwan
- Prior art keywords
- contact lens
- critical point
- area
- central
- annular
- Prior art date
Links
Images
Landscapes
- Eyeglasses (AREA)
Abstract
Description
本發明是有關於一種隱形眼鏡及隱形眼鏡產品,且特別是有關於一種可緩和離開中心區的屈光度提升幅度並可預防近視或控制近視的隱形眼鏡及隱形眼鏡產品。The present invention relates to a contact lens and a contact lens product, and in particular to a contact lens and a contact lens product which can alleviate the increase of diopter away from the central area and can prevent or control myopia.
傳統具有視力控制功能的隱形眼鏡,其離焦程度的設計通常自離開中心區後,即迅速提升屈光度,其屈光度的變化劇烈,使得配戴者的不適感嚴重,而無法長時間配合治療療程,導致視力控制的效果大幅降低。再者,傳統具有正反辨識功能的隱形眼鏡,係於隱形眼鏡的表面設置凹陷的微小溝槽,亦或設置凸起的小圓點,然而,凹陷的微小溝槽易使隱形眼鏡破碎,凸起的小圓點易使配戴者的異物感嚴重。此外,傳統具有視力控制功能的隱形眼鏡無法控制光通量,過多的光通量易導致配戴者畏光,過少的光通量則會造成影像不清。因此,如何改良隱形眼鏡的結構,使其具有視力控制功能並可避免前述缺失,遂成為相關業者的目標。The defocus degree of traditional contact lenses with vision control function is usually designed to increase the diopter rapidly after leaving the central area. The change in diopter is drastic, which makes the wearer feel serious discomfort and cannot cooperate with the treatment for a long time. The effect of vision control is greatly reduced. Furthermore, the traditional contact lenses with positive and negative identification function are provided with small concave grooves or raised dots on the surface of the contact lenses. However, the small concave grooves are easy to break the contact lenses, and the convex The raised dots are easy to make the wearer feel a serious foreign body sensation. In addition, traditional contact lenses with vision control function cannot control the luminous flux. Too much luminous flux will easily cause the wearer to be sensitive to light, and too little luminous flux will cause blurred images. Therefore, how to improve the structure of the contact lens so that it has the function of vision control and can avoid the aforementioned defects has become the goal of the relevant industry.
本發明之一目的是提供一種隱形眼鏡及隱形眼鏡產品,其中隱形眼鏡可預防近視或控制近視,其環形區包含至少一臨界點,可有效緩和離開中心區的屈光度提升幅度,提升配戴的舒適性,而有助提升長周期的治療可能性。One object of the present invention is to provide a contact lens and a contact lens product, wherein the contact lens can prevent myopia or control myopia, and its annular zone contains at least one critical point, which can effectively ease the increase in diopter away from the central zone and improve wearing comfort Sex, which helps to improve the possibility of long-term treatment.
依據本發明提供一種隱形眼鏡,包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。其中環形區包含至少一臨界點值,最靠近中心點的臨界點值為一第一臨界點值,第一臨界點值為一高臨界點值,且隱形眼鏡包含至少一色樣部,色樣部為具方向性辨識的圖樣,環形區的最大屈光度為PPmax,中心區的屈光度為POWC,第一臨界點值為PCP1,中心區的最大直徑為DiC,其滿足下列條件: 12.0 D ≤ PPmax-POWC ≤ 20.0 D; 2.0 D ≤ PCP1-POWC < 15.0 D;以及 2.4 mm < DiC ≤ 4.5 mm。According to the present invention there is provided a contact lens comprising a central zone, an annular zone and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. Wherein the annular area includes at least one critical point value, the critical point value closest to the central point is a first critical point value, the first critical point value is a high critical point value, and the contact lens includes at least one color sample portion, the color sample portion It is a pattern with directional recognition, the maximum diopter of the annular area is PPmax, the diopter of the central area is POWC, the first critical point value is PCP1, and the maximum diameter of the central area is DiC, which meets the following conditions: 12.0 D ≤ PPmax-POWC ≤ 20.0 D; 2.0 D ≤ PCP1-POWC < 15.0 D; and 2.4 mm < DiC ≤ 4.5 mm.
依據本發明再提供一種隱形眼鏡產品,包含前述的隱形眼鏡以及浸潤溶液,隱形眼鏡浸泡於浸潤溶液中,其中隱形眼鏡與浸潤溶液中至少一者包含睫狀肌麻痺劑。According to the present invention, there is further provided a contact lens product, comprising the aforementioned contact lens and an infiltration solution, wherein the contact lens is soaked in the infiltration solution, wherein at least one of the contact lens and the infiltration solution contains a cycloplegic agent.
當PPmax-POWC滿足上述條件時,可提供較緩和的離焦程度,有助減輕長時間配戴的不舒服性,提供較長時間的可使用性以達成近視控制目的。When PPmax-POWC satisfies the above conditions, it can provide a moderate degree of defocus, help reduce the discomfort of wearing for a long time, and provide a longer usability to achieve the purpose of myopia control.
當PCP1-POWC滿足上述條件時,有助於適當小幅度調升離焦程度,提升預防近視或控制近視的效果。When PCP1-POWC satisfies the above conditions, it is helpful to increase the degree of defocus appropriately and slightly, and improve the effect of preventing or controlling myopia.
當DiC滿足上述條件時,可依配戴者狀況提供清晰的中央視野範圍,並有助減少配戴時的不適感。When DiC satisfies the above conditions, it can provide a clear central visual field according to the wearer's condition, and help reduce the discomfort during wearing.
<第一實施方式><First Embodiment>
第1圖繪示依照本發明第一實施方式的一種隱形眼鏡100的分區示意圖。第1圖中,隱形眼鏡100包含一中心區110、一環形區120以及一周邊區130。中心區110包含隱形眼鏡100的中心點O,環形區120對稱環繞中心區110,周邊區130對稱環繞環形區120,環形區120包含至少一臨界點值。藉由臨界點值的設置,可提供階段式大幅度或小幅度的緩和效果,而可有效緩和離開中心區110的屈光度提升幅度,提升配戴的舒適性,而有助提升長周期的治療可能性。FIG. 1 shows a schematic partition diagram of a
中心區110的屈光度為POWC,其可滿足下列條件:-0.50 D ≤ POWC ≤ 0.50 D。藉此,當使用於潛在近視趨勢的患者時,可使光線良好聚焦於視網膜上,提供清晰舒適的影像。具體來說,中心區110配置低度數或無度數的屈光度,再搭配環形區120適當且緩和的離焦設計,可使光線聚焦於視網膜前以達成近視預防與避免眼軸增長。或者,其可滿足下列條件:-0.25 D ≤ POWC ≤ 0.25 D。The diopter of the
中心區110的屈光度為POWC,其可滿足下列條件:-8.00 D ≤ POWC < 0 D。藉此,當使用於具有中低度近視患者時,中心區110的屈光度可提供矯正近視功能,視需求調整中心區110的屈光度,使光線良好聚焦於視網膜上,提供清晰舒適的影像。或者,其可滿足下列條件:-7.00 D ≤ POWC ≤ -0.25D。或者,其可滿足下列條件:-6.50 D ≤ POWC < 0 D。或者,其可滿足下列條件:-5.50 D ≤ POWC < 0 D。或者,其可滿足下列條件:-4.50 D ≤ POWC < 0 D。The diopter of the
中心區110的屈光度為POWC,環形區120的最大屈光度為PPmax,其滿足下列條件:2.00 D ≤ |PPmax-POWC| ≤ 20.00 D。藉此,環形區120設計有屈光度的提升,使得環形區120的光線會聚焦於視網膜前,藉由離焦效果以達成預防近視與控制近視功能,有效避免眼軸增長的問題。或者,其可滿足下列條件:2.00 D ≤ |PPmax-POWC| ≤ 8.00 D。或者,其可滿足下列條件:3.50 D ≤ |PPmax-POWC| ≤ 19.00 D。或者,其可滿足下列條件:5.50 D ≤ |PPmax-POWC| ≤ 17.00 D。或者,其可滿足下列條件:8.00 D ≤ |PPmax-POWC| ≤ 15.00 D。或者,其可滿足下列條件:9.50 D ≤ |PPmax-POWC| ≤ 15.50 D。The diopter of the
環形區120的最大屈光度為PPmax,其可滿足下列條件:0 D ≤ PPmax ≤ 15.00 D。藉此,可依照配戴者需求適當提升中心區110外的離焦效果。或者,其可滿足下列條件:0.50 D ≤ PPmax ≤ 13.00 D。或者,其可滿足下列條件:1.50 D ≤ PPmax ≤ 12.50 D。或者,其可滿足下列條件:2.00 D ≤ PPmax ≤ 10.5 D。或者,其可滿足下列條件:2.00 D ≤ PPmax ≤ 9.00 D。The maximum diopter of the
環形區120可包含至少一高臨界點值,高臨界點值為PPH,其可滿足下列條件:-5.00 D ≤ PPH ≤ 20.00 D。藉此,可緩和屈光度提升的變化程度。或者,其可滿足下列條件:-5.00D ≤ PPH ≤ 18.00 D,或者,其可滿足下列條件:-3.00 D ≤ PPH ≤ 16.00 D。或者,其可滿足下列條件:-1.00 D ≤ PPH ≤ 16.00 D。或者,其可滿足下列條件:-1.00 D ≤ PPH ≤ 14.00 D。The
環形區120可包含至少一中臨界點值,環形區120的中臨界點值為PPM,其可滿足下列條件:-6.00 D ≤ PPM ≤ 0 D。藉此,可於視網膜周邊提供部分清楚對焦區域,減緩配戴隱形眼鏡100的不適感。或者,其可滿足下列條件:-3.00 D ≤ PPM ≤ 0 D。The
環形區120可包含至少一低臨界點值,低臨界點值為PPL,其可滿足下列條件:-10.00 D ≤ PPL ≤ 0 D。藉此,可增加屈光度提升的設計自由度並具有緩和屈光度變化效果。或者,其可滿足下列條件:-9.00 D ≤ PPL ≤ 0 D。或者,其可滿足下列條件:-4.00 D ≤ PPL ≤ 0 D。The
環形區120可包含至少一高臨界點值,環形區120的最大屈光度為PPmax,高臨界點值為PPH,其可滿足下列條件:-5.00 ≤ PPmax/PPH ≤ 60.00。藉此,可依配戴者狀況設置較佳的中心區110外離焦程度。此外,高臨界點值的設置有助於分段式提升離焦程度,減緩周邊高離焦設計的不適感。或者,其可滿足下列條件:-5.00 ≤ PPmax/PPH ≤ 30.00。或者,其可滿足下列條件:-5.00 ≤ PPmax/PPH ≤ 20.00。或者,其可滿足下列條件:-3.00 ≤ PPmax/PPH ≤ 20.00。或者,其可滿足下列條件:-5.00 ≤ PPmax/PPH ≤ 15.00。或者,其可滿足下列條件:-3.00 ≤ PPmax/PPH ≤ 18.00。或者,其可滿足下列條件:-3.00 ≤ PPmax/PPH ≤ 15.00。或者,其可滿足下列條件:-3.00 ≤ PPmax/PPH ≤ 10.00。或者,其可滿足下列條件:-3.00 ≤ PPmax/PPH ≤ 9.00。或者,其可滿足下列條件:-3.00 ≤ PPmax/PPH ≤ 5.00。The
環形區120可包含至少一低臨界點值,環形區120的最大屈光度為PPmax,低臨界點值為PPL,其可滿足下列條件:-40.00 ≤ PPmax/PPL ≤ 0。藉此,可依配戴者狀況設置較佳的中心區110外的離焦程度,低臨界點值的設置有助於漸進式緩和離焦程度,降低高離焦的設計困難度。或者,其可滿足下列條件:-30.00 ≤ PPmax/PPL ≤ 0。或者,其可滿足下列條件:-25.00 ≤ PPmax/PPL ≤ 0。或者,其可滿足下列條件:-20.00 ≤ PPmax/PPL ≤ 0。或者,其可滿足下列條件:-15.00 ≤ PPmax/PPL ≤ 0。或者,其可滿足下列條件:-10.00 ≤ PPmax/PPL ≤ 0。The
中心區110的最大直徑為DiC,其可滿足下列條件:1.0 mm ≤ DiC ≤ 4.5 mm。藉此,可依配戴者狀況提供清晰的中央視野範圍,並有助減少配戴時的不適感。或者,其可滿足下列條件:1.4 mm ≤ DiC ≤ 4.5 mm。或者,其可滿足下列條件:1.4 mm ≤ DiC ≤ 3.5 mm。或者,其可滿足下列條件:2.0 mm ≤ DiC ≤ 3.0 mm。The maximum diameter of the
環形區120的最大直徑為DiP,其可滿足下列條件:DiP ≤ 8.0 mm。藉此,提供適當的環形區120範圍以達成近視控制與近視預防。The maximum diameter of the
環形區120可包含至少一臨界點值,最靠近中心點O的臨界點值為第一臨界點值,且第一臨界點值可為低臨界點值。藉此,可使屈光度適度下降並緩和屈光度變化,減少離焦對配戴者造成的不適感。The
環形區120可包含至少二臨界點值,由內至外分別為第一臨界點值以及第二臨界點值,第一臨界點值可為高臨界點值。藉此,可於環形區120的內側達到立即升高屈光度,有助於提升預防近視或控制近視的強度。The ring-shaped
第一臨界點值可為高臨界點值,且第二臨界點值為低臨界點值。當第一臨界點為高臨界點,可於環形區120的內側達到立即升高屈光度,有助於提升預防近視或控制近視的強度,進一步配合第二臨界點為低臨界點,可使屈光度適度下降並緩和屈光度變化,減少離焦對配戴者造成的不適感。The first threshold value may be a high threshold value, and the second threshold value may be a low threshold value. When the first critical point is a high critical point, the diopter can be increased immediately inside the
第二臨界點值可為高臨界點值。藉此,有助於提升離焦程度,於短周期獲得預防近視或控制近視的效果。The second threshold value may be a high threshold value. In this way, it helps to increase the degree of defocus, and achieve the effect of preventing or controlling myopia in a short period of time.
第二臨界點值可為中臨界點值。藉此,有助於緩和離焦程度,使環形區120部分具清楚對焦效果以增加配戴者視覺舒適性。The second threshold value may be an intermediate threshold value. In this way, it is helpful to alleviate the degree of defocus, and make the ring-shaped
第二臨界點值可為低臨界點值。藉此,有助於緩和離焦程度,減少配戴時的不適感。The second threshold value may be a low threshold value. In this way, it helps to ease the degree of defocus and reduce the discomfort when wearing.
中心區110的屈光度為POWC,第一臨界點值為PCP1,其可滿足下列條件:0 D < PCP1-POWC ≤ 3.80 D。藉此,設計較佳第一臨界點與中心的屈光度差值,有助於適當小幅度調升離焦程度,提升預防近視或控制近視的效果。或者,其可滿足下列條件:0 D < PCP1-POWC ≤ 3.5 D。The diopter of the
中心區110的屈光度為POWC,第一臨界點值為PCP1,其可滿足下列條件:4.00 D ≤ PCP1-POWC ≤ 20.00 D。藉此,設計較佳第一臨界點與中心區110的屈光度差值,有助於以適當且階段式的幅度調升離焦程度,提高預防近視或控制近視的效果。或者,其可滿足下列條件:4.5 D ≤ PCP1-POWC ≤ 18 D。或者,其可滿足下列條件:4.5 D ≤ PCP1-POWC ≤ 10 D。The diopter of the
中心區110的屈光度為POWC,第一臨界點值為PCP1,其可滿足下列條件:-6.00 D ≤ PCP1-POWC ≤ 10 D。藉此,設計較佳第一臨界點與中心區110的屈光度差值,有助於適當小幅度調整離焦程度,提升預防近視或控制近視的效果。或者,其可滿足下列條件:-6.00 D ≤ PCP1-POWC < 0 D。或者,其可滿足下列條件:-5.00 D ≤ PCP1-POWC < 0 D。或者,其可滿足下列條件:-4.00 D ≤ PCP1-POWC < 0 D。The diopter of the
第一臨界點值為PCP1,第二臨界點值為PCP2,其可滿足下列條件:-14.00 D ≤ PCP2-PCP1 ≤ 16 D。藉此,可避免離焦設計可能造成的不適感。The first critical point value is PCP1, and the second critical point value is PCP2, which can satisfy the following conditions: -14.00 D ≤ PCP2-PCP1 ≤ 16 D. In this way, possible discomfort caused by the out-of-focus design can be avoided.
第一臨界點值為PCP1,第二臨界點值為PCP2,其可滿足下列條件:-7.00 D ≤ PCP2-PCP1 ≤ 0 D。藉此,設計較佳第二臨界點與第一臨界點的屈光度差值,以小幅度減少屈光度,可減緩和避免離焦設計可能造成的不適感。或者,其可滿足下列條件:-6.00 D ≤ PCP2-PCP1 ≤ 0 D。或者,其可滿足下列條件:-5.00 D ≤ PCP2-PCP1 ≤ 0 D。The first critical point value is PCP1, and the second critical point value is PCP2, which can satisfy the following conditions: -7.00 D ≤ PCP2-PCP1 ≤ 0 D. In this way, the diopter difference between the second critical point and the first critical point is designed to reduce the diopter in a small range, which can slow down and avoid the discomfort that may be caused by the out-of-focus design. Alternatively, it may satisfy the following condition: -6.00 D ≤ PCP2-PCP1 ≤ 0 D. Alternatively, it may satisfy the following condition: -5.00 D ≤ PCP2-PCP1 ≤ 0 D.
第一臨界點值為PCP1,第二臨界點值為PCP2,其可滿足下列條件:-14.00 D ≤ PCP2-PCP1 ≤ -7.50 D。藉此,設計較佳第二臨界點與第一臨界點的屈光度差值,以較大幅度降低屈光度,可快速改善離焦設計可能造成的不適感。或者,其可滿足下列條件:-12.00 D ≤ PCP2-PCP1 ≤ -7.50 D。或者,其可滿足下列條件:-10.00 D ≤ PCP2-PCP1 ≤ -7.50 D。The first critical point value is PCP1, and the second critical point value is PCP2, which can satisfy the following condition: -14.00 D ≤ PCP2-PCP1 ≤ -7.50 D. In this way, designing a better diopter difference between the second critical point and the first critical point can greatly reduce the diopter, which can quickly improve the discomfort that may be caused by the out-of-focus design. Alternatively, it may satisfy the following condition: -12.00 D ≤ PCP2-PCP1 ≤ -7.50 D. Alternatively, it may satisfy the following condition: -10.00 D ≤ PCP2-PCP1 ≤ -7.50 D.
中心區110的屈光度為POWC,第一臨界點值為PCP1,第二臨界點值為PCP2,其可滿足下列條件:-25 ≤ (PCP2-PCP1)/(PCP1-POWC) ≤ 0。藉此,可減少不適感與提升預防近視或控制近視的成功率。The diopter of the
中心區110的屈光度為POWC,第一臨界點值為PCP1,第二臨界點值為PCP2,其可滿足下列條件:-1.75 ≤ (PCP2-PCP1)/(PCP1-POWC) ≤ 0。藉此,設計較佳屈光度差值得比值,以小幅度的屈光度變化達到較緩和的離焦設計,有助於配戴者長週期配戴與漸進適應,提升預防近視或控制近視的成功率。或者,其可滿足下列條件:-1.6 ≤ (PCP2-PCP1)/(PCP1-POWC) ≤ 0。The diopter of the
中心區110的屈光度為POWC,第一臨界點值為PCP1,第二臨界點值為PCP2,其可滿足下列條件:-25 ≤ (PCP2-PCP1)/(PCP1-POWC) ≤ -1.9。藉此,設計較佳屈光度差值得比值,以較大幅度的屈光度變化達到較大程度的離焦設計,有助於配戴者於短周期獲得預防近視或控制近視的效果。或者,其可滿足下列條件:-15 ≤ (PCP2-PCP1)/(PCP1-POWC) ≤ -2。The diopter of the
環形區120可包含至少三臨界點值,由內至外分別為第一臨界點值、第二臨界點值以及第三臨界點值,第二臨界點值為PCP2,第三臨界點值為PCP3,其可滿足下列條件:-20.00 D ≤ PCP3-PCP2 ≤ 20.00 D。藉此,可減少不適感與提高預防近視或控制近視的效果。The
第二臨界點值為PCP2,第三臨界點值為PCP3,其可滿足下列條件:0 D ≤ PCP3-PCP2 ≤ 12.00 D。藉此,設計較佳第三臨界點與第二臨界點的屈光度差值,以小幅度緩和提升屈光度,可提高患者於預防近視或控制近視療程的適應力。The second critical point value is PCP2, and the third critical point value is PCP3, which can satisfy the following conditions: 0 D ≤ PCP3-PCP2 ≤ 12.00 D. In this way, designing a better diopter difference between the third critical point and the second critical point to moderately increase the diopter in a small range can improve the patient's adaptability in the course of myopia prevention or myopia control.
第二臨界點值為PCP2,第三臨界點值為PCP3,其可滿足下列條件:14.00 D ≤ PCP3-PCP2 ≤ 20.00 D。藉此,設計較佳第三臨界點與第二臨界點的屈光度差值,以較大幅度提升屈光度,可達到較強程度的提升預防近視或控制近視的效果。The second critical point value is PCP2, and the third critical point value is PCP3, which can satisfy the following conditions: 14.00 D ≤ PCP3-PCP2 ≤ 20.00 D. In this way, designing a better diopter difference between the third critical point and the second critical point can greatly increase the diopter, which can achieve a stronger effect of preventing myopia or controlling myopia.
第三臨界點值可為高臨界點值。藉此,有助於提升離焦程度,於短周期獲得預防近視或控制近視的效果。The third threshold value may be a high threshold value. In this way, it helps to increase the degree of defocus, and achieve the effect of preventing or controlling myopia in a short period of time.
第三臨界點值可為中臨界點值。藉此,有助於緩和離焦程度,使環形區120部分具清楚對焦效果以增加配戴者視覺舒適性。The third threshold value may be an intermediate threshold value. In this way, it is helpful to alleviate the degree of defocus, and make the ring-shaped
第三臨界點值可為低臨界點值。藉此,有助於緩和離焦程度,減少配戴時的不適感。The third threshold value may be a low threshold value. In this way, it helps to ease the degree of defocus and reduce the discomfort when wearing.
環形區120可包含至少四臨界點值,由內至外分別為第一臨界點值、第二臨界點值、第三臨界點值以及第四臨界點值,第三臨界點值為PCP3,第四臨界點值為PCP4,其可滿足下列條件:-15.00 D ≤ PCP4-PCP3 ≤ 12.00 D。藉此,以較大幅度提升屈光度,可達到較強程度的提升預防近視或控制近視的效果。The
第四臨界點值可為高臨界點值。藉此,有助於提升離焦程度,於短周期獲得預防近視或控制近視的效果。The fourth threshold value may be a high threshold value. In this way, it helps to increase the degree of defocus, and achieve the effect of preventing or controlling myopia in a short period of time.
第四臨界點值可為低臨界點值。藉此,有助於緩和離焦程度,減少配戴時的不適感。The fourth threshold value may be a low threshold value. In this way, it helps to ease the degree of defocus and reduce the discomfort when wearing.
環形區120可包含至少五臨界點值,由內至外分別為第一臨界點值、第二臨界點值、第三臨界點值、第四臨界點值以及第五臨界點值,第四臨界點值為PCP4,第五臨界點值為PCP5,其可滿足下列條件:-5.00 D ≤ PCP5-PCP4 ≤ 5.00 D。藉此,以小幅度緩和提升屈光度,可提高患者於預防近視或控制近視療程的適應力。The
第五臨界點值可為高臨界點值。藉此,有助於提升離焦程度,於短周期獲得預防近視或控制近視的效果。The fifth threshold value may be a high threshold value. In this way, it helps to increase the degree of defocus, and achieve the effect of preventing or controlling myopia in a short period of time.
第五臨界點值可為低臨界點值。藉此,有助於緩和離焦程度,減少配戴時的不適感。The fifth threshold value may be a low threshold value. In this way, it helps to ease the degree of defocus and reduce the discomfort when wearing.
環形區120可包含至少六臨界點值,由內至外分別為第一臨界點值、第二臨界點值、第三臨界點值、第四臨界點值、第五臨界點值以及第六臨界點值,第五臨界點值為PCP5,第六臨界點值為PCP6,其可滿足下列條件:-5.00 D ≤ PCP6-PCP5 ≤ 15.00 D。藉此,以較大幅度提升屈光度,可達到較強程度的提升預防近視或控制近視的效果。The
第六臨界點值可為高臨界點值。藉此,有助於提升離焦程度,於短周期獲得預防近視或控制近視的效果。The sixth threshold value may be a high threshold value. In this way, it helps to increase the degree of defocus, and achieve the effect of preventing or controlling myopia in a short period of time.
第六臨界點值可為低臨界點值。藉此,有助於緩和離焦程度,減少配戴時的不適感。The sixth threshold value may be a low threshold value. In this way, it helps to ease the degree of defocus and reduce the discomfort when wearing.
前述臨界點值、高臨界點值、低臨界點值以及中臨界點值定義如下,隱形眼鏡100的環形區120可包含至少一臨界點(圖未繪示),臨界點的屈光度稱為臨界點值,依據臨界點值與中心區110屈光度的關係,將臨界點分為高臨界點(CH)、低臨界點(CL)以及中臨界點(CM)。臨界點值高於中心區110屈光度的臨界點稱為高臨界點,其臨界點值稱為高臨界點值;臨界點值低於中心區110屈光度的臨界點稱為低臨界點,其臨界點值稱為低臨界點值;臨界點值等於中心區110屈光度的臨界點稱為中臨界點,其臨界點值稱為中臨界點值。The aforementioned critical point value, high critical point value, low critical point value, and middle critical point value are defined as follows. The
<第二實施方式><Second Embodiment>
第2A圖繪示依照本發明第二實施方式的一種隱形眼鏡200的分區示意圖,第2B圖繪示第2A圖中隱形眼鏡200的側視圖,第2C圖繪示第2A圖中隱形眼鏡200的俯視圖。第2A圖至第2C圖中,隱形眼鏡200包含一中心區210、一環形區220以及一周邊區230。中心區210包含隱形眼鏡200的中心點O,環形區220對稱環繞中心區210,周邊區230對稱環繞環形區220,環形區220包含至少一臨界點值。周邊區230可包含至少一色樣部。FIG. 2A shows a schematic partition diagram of a
具體來說,在第二實施方式中,周邊區230包含二色樣部,分別為第一色樣部240A與第二色樣部240B,第一色樣部240A的圖樣為環狀,第二色樣部240B的圖樣為輻射狀。第一色樣部240A的顏色可選自紅、橙、黃、綠、藍、靛、紫、黑、白、銀或金色,第二色樣部240B的顏色與第一色樣部240A的顏色不同。藉此,不同顏色具有不同的可見光穿透效果,選擇適當顏色可有效控制光線穿透能力(提升或減少光通量),深顏色的色樣部可減少畏光效果,淺顏色的色樣部可提升光通量,且色樣部透光率較低,具有高度遮光功效,減少耀光與雜光干擾視力控制效果,至少設置第一色樣部240A與第二色樣部240B兩種色樣部,可選擇性調配減少雜散光效果。Specifically, in the second embodiment, the
在其他實施方式中,色樣部的最小內半徑可涵蓋部分環形區,使其具有遮蔽環形區周邊的雜散光線,有助於避免干擾離焦處成像的效果,減少配戴者的不適感。In other embodiments, the minimum inner radius of the color sample part can cover part of the annular area, so that it can shield the stray light around the annular area, which helps to avoid interfering with the imaging effect at the out-of-focus area and reduces the wearer's discomfort .
關於隱形眼鏡200的其他細節可與第1圖的隱形眼鏡100相同,在此不另贅述。Other details about the
<第三實施方式><Third Embodiment>
第3A圖繪示依照本發明第三實施方式的一種隱形眼鏡300的分區示意圖,第3B圖繪示第3A圖中隱形眼鏡300的側視圖,第3C圖繪示第3A圖中隱形眼鏡300的俯視圖。第3A圖至第3C圖中,隱形眼鏡300包含一中心區310、一環形區320以及一周邊區330。中心區310包含隱形眼鏡300的中心點O,環形區320對稱環繞中心區310,周邊區330對稱環繞環形區320,環形區320包含至少一臨界點值。周邊區330可包含至少一色樣部。FIG. 3A shows a schematic partition diagram of a
具體來說,在第三實施方式中,周邊區330包含二色樣部,分別為第一色樣部340A與第二色樣部340B,第一色樣部340A的圖樣為環狀,第二色樣部340B的圖樣為為多個L,藉由第二色樣部340B配置具方向性辨識的圖樣,有助於達成隱形眼鏡300的正反面辨識功能,可提升配戴時的正確性,增加配戴的方便性與效率。第一色樣部340A的顏色可選自紅、橙、黃、綠、藍、靛、紫、黑、白、銀或金色,第二色樣部340B的顏色與第一色樣部340A的顏色不同。藉此,不同顏色具有不同的可見光穿透效果,選擇適當顏色可有效控制光線穿透能力(提升或減少光通量),深顏色的色樣部可減少畏光效果,淺顏色的色樣部可提升光通量,且色樣部透光率較低,具有高度遮光功效,減少耀光與雜光干擾視力控制效果,至少設置第一色樣部340A與第二色樣部340B兩種色樣部,可選擇性調配減少雜散光效果。Specifically, in the third embodiment, the
在其他實施方式中,色樣部的最小內半徑可涵蓋部分環形區,使其具有遮蔽環形區周邊的雜散光線,有助於避免干擾離焦處成像的效果,減少配戴者的不適感。In other embodiments, the minimum inner radius of the color sample part can cover part of the annular area, so that it can shield the stray light around the annular area, which helps to avoid interfering with the imaging effect at the out-of-focus area and reduces the wearer's discomfort .
關於隱形眼鏡300的其他細節可與第1圖的隱形眼鏡100相同,在此不另贅述。Other details about the
<第四實施方式><Fourth Embodiment>
第4圖繪示依照本發明第四實施方式的一種隱形眼鏡400的阻光環450配置示意圖。第4圖中,隱形眼鏡400包含一中心區(未另標示)、一環形區(未另標示)以及一周邊區(未另標示)。中心區包含隱形眼鏡400的中心點O,環形區對稱環繞中心區,周邊區對稱環繞環形區,環形區包含至少一臨界點值。隱形眼鏡400的中心區外可包含至少一阻光環450。較佳地,阻光環450設置於環形區,藉此,可有效消除離焦區域的雜散光,提升近視控制的治療效果。或者,周邊區可包含至少一阻光環450(由環形區延伸至周邊區,即周邊區僅包含部分的阻光環450),藉此,可避免過多光線進入眼睛產生畏光,並可維持充足的光通量以確保影像的明亮度。FIG. 4 is a schematic diagram showing the configuration of a light-blocking
在第四實施方式中,阻光環450的設置為均勻分布,藉此,可有效減少雜散光的干擾,並可依配戴者的瞳孔大小進行最佳化設計,避免過多光線進入眼睛的畏光問題,並可維持充足的光通量以確保影像的明亮度。前述均勻分布是指有規則的、間斷的或全填滿的設計。然而,本發明並不以此為限。In the fourth embodiment, the light-blocking
在第四實施方式中,阻光環450為實心填滿,然而,在其他方式中,阻光環亦可為間斷式填滿(請參見第10圖)或點狀分布(請參見第11圖)。藉此,可避免過多光線進入眼睛產生畏光,並可維持充足的光通量以確保影像的明亮度。In the fourth embodiment, the light-blocking
阻光環450的顏色可選自紅、橙、黃、綠、藍、靛、紫、黑、白、銀或金色。藉此,選擇適當的顏色可提升或減少光通量,深顏色的阻光環450降低畏光效果,淺顏色的阻光環可提升視野明亮度。The color of the
在第四實施方式中,阻光環450的最小內直徑為DBi,其可滿足下列條件:DBi = 7.04 mm。在其他實施方式中,阻光環的最小內直徑為DBi,其可滿足下列條件:3.5 mm ≤ DBi ≤ 11.0 mm。藉此,可避免過多光線進入眼睛的畏光問題,並可維持充足的光通量以確保影像的明亮度。或者,其可滿足以下條件:3.5 mm ≤ DBi ≤ 10 mm。或者,其可滿足以下條件:4.5 mm ≤ DBi ≤ 10 mm。或者,其可滿足以下條件:4.5 mm ≤ DBi ≤ 9 mm。或者,其可滿足以下條件:4.5 mm ≤ DBi ≤ 8.5 mm。In the fourth embodiment, the minimum inner diameter of the light-blocking
在第四實施方式中,阻光環450的最大外直徑為DBo,其可滿足下列條件:DBo = 9.1 mm。在其他實施方式中,阻光環的最大外直徑為DBo,其可滿足下列條件:6 mm ≤ DBo ≤ 14 mm。藉此,可避免過多光線進入眼睛的畏光問題,並可維持充足的光通量以確保影像的明亮度。或者,其可滿足以下條件:6 mm ≤ DBo ≤ 13 mm。或者,其可滿足以下條件:6.5 mm ≤ DBo ≤ 12.5 mm。或者,其可滿足以下條件:6.0 mm ≤ DBo ≤ 11.0 mm。或者,其可滿足以下條件:7.5 mm ≤ DBo ≤ 12.5 mm。或者,其可滿足以下條件:8.5 mm ≤ DBo ≤ 11.5 mm。In the fourth embodiment, the maximum outer diameter of the light-blocking
在第四實施方式中,隱形眼鏡400的最大外徑為Do,其可滿足下列條件:Do = 14 mm。在其他實施方式中,隱形眼鏡的最大外徑為Do,其可滿足下列條件: 13 mm ≤ Do ≤ 15 mm。藉此,依需求製作最適當的隱形眼鏡大小。In the fourth embodiment, the maximum outer diameter of the
在第四實施方式中,隱形眼鏡400的周邊區可更包含至少一色樣部(圖未繪示),關於色樣部的細節可與第2A圖至第2C圖的隱形眼鏡200或第3A圖至第3C圖的隱形眼鏡300相同,在此不另贅述。關於隱形眼鏡400的其他細節可與第1圖的隱形眼鏡100相同,在此不另贅述。In the fourth embodiment, the peripheral area of the
<第五實施方式><Fifth Embodiment>
第5圖繪示依照本發明第五實施方式的一種隱形眼鏡500的阻光環550配置示意圖。第5圖中,隱形眼鏡500包含一中心區(未另標示)、一環形區(未另標示)以及一周邊區(未另標示)。中心區包含隱形眼鏡500的中心點O,環形區對稱環繞中心區,周邊區對稱環繞環形區,環形區包含至少一臨界點值。隱形眼鏡500的中心區外可包含至少一阻光環550。較佳地,阻光環550設置於環形區。或者,周邊區可包含至少一阻光環550(由環形區延伸至周邊區,即周邊區僅包含部分的阻光環550)。FIG. 5 is a schematic diagram showing the configuration of a light-blocking
在第五實施方式中,阻光環550的設置為均勻分布,且為實心填滿,阻光環550的顏色可選自紅、橙、黃、綠、藍、靛、紫、黑、白、銀或金色。In the fifth embodiment, the light-blocking
在第五實施方式中,阻光環550的最小內直徑為DBi(參見第4圖),阻光環550的最大外直徑為DBo(參見第4圖),隱形眼鏡500的最大外徑為Do,其可滿足下列條件:DBi = 4.02 mm;DBo = 7.18 mm;以及Do = 14 mm。In the fifth embodiment, the minimum inner diameter of the
在第五實施方式中,隱形眼鏡500的周邊區可更包含至少一色樣部(圖未繪示),關於色樣部的細節可與第2A圖至第2C圖的隱形眼鏡200或第3A圖至第3C圖的的隱形眼鏡300相同,在此不另贅述。關於隱形眼鏡500的其他細節可與第1圖的隱形眼鏡100相同,在此不另贅述。In the fifth embodiment, the peripheral area of the
<第六實施方式><Sixth Embodiment>
第6圖繪示依照本發明第六實施方式的一種隱形眼鏡600的阻光環650配置示意圖。第6圖中,隱形眼鏡600包含一中心區(未另標示)、一環形區(未另標示)以及一周邊區(未另標示)。中心區包含隱形眼鏡600的中心點O,環形區對稱環繞中心區,周邊區對稱環繞環形區,環形區包含至少一臨界點值。隱形眼鏡600的中心區外可包含至少一阻光環650。較佳地,阻光環650設置於環形區。或者,周邊區可包含至少一阻光環650(由環形區延伸至周邊區,即周邊區僅包含部分的阻光環650)。FIG. 6 is a schematic diagram showing the configuration of a light-blocking
在第六實施方式中,阻光環650的設置為均勻分布,且為實心填滿,阻光環650的顏色可選自紅、橙、黃、綠、藍、靛、紫、黑、白、銀或金色。In the sixth embodiment, the light-blocking
在第六實施方式中,阻光環650的最小內直徑為DBi(參見第4圖),阻光環650的最大外直徑為DBo(參見第4圖),隱形眼鏡600的最大外徑為Do,其可滿足下列條件:DBi = 5.95 mm;DBo = 12.07 mm;以及Do = 14 mm。In the sixth embodiment, the minimum inner diameter of the
在第六實施方式中,隱形眼鏡600的周邊區可更包含至少一色樣部(圖未繪示),關於色樣部的細節可與第2A圖至第2C圖的隱形眼鏡200或第3A圖至第3C圖的隱形眼鏡300相同,在此不另贅述。關於隱形眼鏡600的其他細節可與第1圖的隱形眼鏡100相同,在此不另贅述。In the sixth embodiment, the peripheral area of the
<第七實施方式><Seventh Embodiment>
第7圖繪示依照本發明第七實施方式的一種隱形眼鏡700的阻光環750配置示意圖。第7圖中,隱形眼鏡700包含一中心區(未另標示)、一環形區(未另標示)以及一周邊區(未另標示)。中心區包含隱形眼鏡700的中心點O,環形區對稱環繞中心區,周邊區對稱環繞環形區,環形區包含至少一臨界點值。隱形眼鏡700的中心區外可包含至少一阻光環750。較佳地,阻光環750設置於環形區。或者,周邊區可包含至少一阻光環750(由環形區延伸至周邊區,即周邊區僅包含部分的阻光環750)。FIG. 7 is a schematic diagram showing a configuration of a
在第七實施方式中,阻光環750的設置為均勻分布,且為實心填滿,阻光環750的顏色可選自紅、橙、黃、綠、藍、靛、紫、黑、白、銀或金色。In the seventh embodiment, the light-blocking
在第七實施方式中,阻光環750的最小內直徑為DBi(參見第4圖),阻光環750的最大外直徑為DBo(參見第4圖),隱形眼鏡700的最大外徑為Do,其可滿足下列條件:DBi = 7.91 mm;DBo = 11.02 mm;以及Do = 14 mm。In the seventh embodiment, the minimum inner diameter of the
在第七實施方式中,隱形眼鏡700的周邊區可更包含至少一色樣部(圖未繪示),關於色樣部的細節可與第2A圖至第2C圖的隱形眼鏡200或第3A圖至第3C圖的隱形眼鏡300相同,在此不另贅述。關於隱形眼鏡700的其他細節可與第1圖的隱形眼鏡100相同,在此不另贅述。In the seventh embodiment, the peripheral area of the
<第八實施方式><Eighth Embodiment>
第8圖繪示依照本發明第八實施方式的一種隱形眼鏡800的阻光環850配置示意圖。第8圖中,隱形眼鏡800包含一中心區(未另標示)、一環形區(未另標示)以及一周邊區(未另標示)。中心區包含隱形眼鏡800的中心點O,環形區對稱環繞中心區,周邊區對稱環繞環形區,環形區包含至少一臨界點值。隱形眼鏡800的中心區外可包含至少一阻光環850。較佳地,阻光環850設置於環形區。或者,周邊區可包含至少一阻光環850(由環形區延伸至周邊區,即周邊區僅包含部分的阻光環850)。FIG. 8 is a schematic diagram showing the configuration of a light-blocking
在第八實施方式中,阻光環850的設置為均勻分布,且為實心填滿,阻光環850的顏色可選自紅、橙、黃、綠、藍、靛、紫、黑、白、銀或金色。In the eighth embodiment, the light-blocking
在第八實施方式中,阻光環850的最小內直徑為DBi(參見第4圖),阻光環850的最大外直徑為DBo(參見第4圖),隱形眼鏡800的最大外徑為Do,其可滿足下列條件:DBi = 5.03 mm;DBo = 8.1 mm;以及Do = 14 mm。In the eighth embodiment, the minimum inner diameter of the
在第八實施方式中,隱形眼鏡800的周邊區可更包含至少一色樣部(圖未繪示),關於色樣部的細節可與第2A圖至第2C圖的隱形眼鏡200或第3A圖至第3C圖的的隱形眼鏡300相同,在此不另贅述。關於隱形眼鏡800的其他細節可與第1圖的隱形眼鏡100相同,在此不另贅述。In the eighth embodiment, the peripheral area of the
<第九實施方式><Ninth Embodiment>
第9圖繪示依照本發明第九實施方式的一種隱形眼鏡900的阻光環950配置示意圖。第9圖中,隱形眼鏡900包含一中心區(未另標示)、一環形區(未另標示)以及一周邊區(未另標示)。中心區包含隱形眼鏡900的中心點O,環形區對稱環繞中心區,周邊區對稱環繞環形區,環形區包含至少一臨界點值。隱形眼鏡900的中心區外可包含至少一阻光環950。較佳地,阻光環950設置於環形區。或者,周邊區可包含至少一阻光環950(由環形區延伸至周邊區,即周邊區僅包含部分的阻光環950)。FIG. 9 is a schematic diagram showing the configuration of a light-blocking
在第九實施方式中,阻光環950的設置為均勻分布,且為實心填滿,阻光環950的顏色可選自紅、橙、黃、綠、藍、靛、紫、黑、白、銀或金色。In the ninth embodiment, the light-blocking
在第九實施方式中,阻光環950的最小內直徑為DBi(參見第4圖),阻光環950的最大外直徑為DBo(參見第4圖),隱形眼鏡900的最大外徑為Do,其可滿足下列條件:DBi =7.58 mm;DBo = 10.15 mm;以及Do = 14 mm。In the ninth embodiment, the minimum inner diameter of the
在第九實施方式中,隱形眼鏡900的周邊區可更包含至少一色樣部(圖未繪示),關於色樣部的細節可與第2A圖至第2C圖的隱形眼鏡200或第3A圖至第3C圖的的隱形眼鏡300相同,在此不另贅述。關於隱形眼鏡900的其他細節可與第1圖的隱形眼鏡100相同,在此不另贅述。In the ninth embodiment, the peripheral area of the
<第十實施方式><Tenth Embodiment>
第10圖繪示依照本發明第十實施方式的一種隱形眼鏡1000的阻光環1050配置示意圖。第10圖中,隱形眼鏡1000包含一中心區(未另標示)、一環形區(未另標示)以及一周邊區(未另標示)。中心區包含隱形眼鏡1000的中心點O,環形區對稱環繞中心區,周邊區對稱環繞環形區,環形區包含至少一臨界點值。隱形眼鏡1000的中心區外可包含至少一阻光環1050。較佳地,阻光環1050設置於環形區。或者,周邊區可包含至少一阻光環1050(由環形區延伸至周邊區,即周邊區僅包含部分的阻光環1050)。FIG. 10 is a schematic diagram showing the arrangement of a light-
在第十實施方式中,阻光環1050的設置為均勻分布,且為間斷式填滿,阻光環1050的顏色可選自紅、橙、黃、綠、藍、靛、紫、黑、白、銀或金色。In the tenth embodiment, the light-blocking
在第十實施方式中,阻光環1050的最小內直徑為DBi(參見第4圖),阻光環1050的最大外直徑為DBo(參見第4圖),隱形眼鏡1000的最大外徑為Do,其可滿足下列條件:DBi =6.79 mm;DBo = 9.1 mm;以及Do = 14 mm。In the tenth embodiment, the minimum inner diameter of the
在第十實施方式中,隱形眼鏡1000的周邊區可更包含至少一色樣部(圖未繪示),關於色樣部的細節可與第2A圖至第2C圖的隱形眼鏡200或第3A圖至第3C圖的的隱形眼鏡300相同,在此不另贅述。關於隱形眼鏡1000的其他細節可與第1圖的隱形眼鏡100相同,在此不另贅述。In the tenth embodiment, the peripheral area of the
<第十一實施方式><Eleventh Embodiment>
第11圖繪示依照本發明第十一實施方式的一種隱形眼鏡1100的阻光環1150配置示意圖。第11圖中,隱形眼鏡1100包含一中心區(未另標示)、一環形區(未另標示)以及一周邊區(未另標示)。中心區包含隱形眼鏡1100的中心點O,環形區對稱環繞中心區,周邊區對稱環繞環形區,環形區包含至少一臨界點值。隱形眼鏡1100的中心區外可包含至少一阻光環1150。較佳地,阻光環1150設置於環形區。或者,周邊區可包含至少一阻光環1150(由環形區延伸至周邊區,即周邊區僅包含部分的阻光環1150)。FIG. 11 is a schematic diagram showing the configuration of a light-
在第十一實施方式中,阻光環1150的設置為均勻分布,且為點狀分布,阻光環1150的顏色可選自紅、橙、黃、綠、藍、靛、紫、黑、白、銀或金色。In the eleventh embodiment, the light-blocking
在第十一實施方式中,隱形眼鏡1100的周邊區可更包含至少一色樣部(圖未繪示),關於色樣部的細節可與第2A圖至第2C圖的隱形眼鏡200或第3A圖至第3C圖的的隱形眼鏡300相同,在此不另贅述。關於隱形眼鏡1100的其他細節可與第1圖的隱形眼鏡100相同,在此不另贅述。In the eleventh embodiment, the peripheral area of the
上述本發明隱形眼鏡中的各技術特徵皆可組合配置,而達到對應之功效。All the technical features in the above-mentioned contact lens of the present invention can be configured in combination to achieve corresponding effects.
<第十二實施方式><Twelfth Embodiment>
第27圖繪示依照本發明第十二實施方式的一種隱形眼鏡產品30的示意圖。第27圖中,隱形眼鏡產品30包含隱形眼鏡10以及浸潤溶液20,隱形眼鏡10浸泡於浸潤溶液20中,關於隱形眼鏡10的細節可與第1圖的隱形眼鏡100至第11圖中的隱形眼鏡1100相同,在此不另贅述。浸潤溶液20可為市面上用於浸泡、保存隱形眼鏡的溶液。FIG. 27 is a schematic diagram of a
隱形眼鏡10與浸潤溶液20中至少一者可包含睫狀肌麻痺劑。亦即,可僅隱形眼鏡10包含睫狀肌麻痺劑,或可僅浸潤溶液20包含睫狀肌麻痺劑,或者可隱形眼鏡10與浸潤溶液20同時包含睫狀肌麻痺劑。At least one of
具體來說,可於製備隱形眼鏡10的組成物中加入睫狀肌麻痺劑,而使最終成形的隱形眼鏡10內含睫狀肌麻痺劑,藉此,配戴隱形眼鏡10時可緩慢釋放出睫狀肌麻痺劑,有助於延緩近視效果,簡化治療程序使患者藉由簡單配戴隱形眼鏡10即具有視力控制功能。或者,可於市面上浸泡、保存隱形眼鏡的溶液加入睫狀肌麻痺劑,而使浸潤溶液20中包含睫狀肌麻痺劑,藉此,睫狀肌麻痺劑可於隱形眼鏡10配戴時即可產生作用,有效發揮立即性效果同時具有簡化治療程序功能。睫狀肌麻痺劑於隱形眼鏡10或於浸潤溶液20中的重量百分比濃度為ConA,其可滿足下列條件:0% < ConA ≤ 1%。或者,其可滿足下列條件:0% < ConA ≤ 0.5%。或者,其可滿足下列條件:0% < ConA ≤ 0.25%。或者,其可滿足下列條件:0% < ConA ≤ 0.1%。或者,其可滿足下列條件:0% < ConA ≤ 0.05%。或者,其可滿足下列條件:0% < ConA ≤ 0.01%。Specifically, a cycloplegic agent can be added to the composition for preparing the
根據上述實施方式,以下提出具體實施例予以詳細說明。According to the above implementation manners, specific examples are provided below for detailed description.
<第一實施例><First embodiment>
第一實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第一實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。第一實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the first embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the first embodiment, please refer to Figure 1, for the color sample part, please refer to Figure 2A to Figure 3C, and for the light blocking ring, please refer to Figure 4 to Figure 11. The contact lens of the first embodiment may optionally contain a cycloplegic agent.
請同時參照表一以及第12圖,表一列出第一實施例的隱形眼鏡的半徑及其所對應的屈光度,第12圖為第一實施例的隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離)。
第一實施例的隱形眼鏡中,中心區的屈光度為POWC,環形區的最大屈光度為PPmax,中心區的最大直徑為DiC,環形區的最大直徑為DiP,環形區的高臨界點值為PPH,環形區的中臨界點值為PPM,環形區的低臨界點值為PPL,第一臨界點值為PCP1,第二臨界點值為PCP2,第三臨界點值為PCP3,第四臨界點值為PCP4,第五臨界點值為PCP5,第六臨界點值為PCP6,關於第一實施例的前述參數的數值及相關條件式的數值請參見表二。
<第二實施例><Second embodiment>
第二實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第二實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含一高臨界點。第二實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the second embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the second embodiment, please refer to Figure 1, for the color sample part, please refer to Figure 2A to Figure 3C, and for the light blocking ring, please refer to Figure 4 to Figure 11. The annular region contains a high critical point. The contact lens of the second embodiment can optionally contain a cycloplegic agent.
請同時參照表三以及第13圖,表三列出第二實施例的隱形眼鏡的半徑及其所對應的屈光度,第13圖為第二實施例的隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離)。
第二實施例的隱形眼鏡中,POWC、PPmax、DiC、DiP、PPH、PPM、PPL、PCP1、PCP2、PCP3、PCP4、PCP5、PCP6等參數的數值及相關條件式的數值請參見表四,前述參數的定義請參照第一實施例。
第二實施例的隱形眼鏡中,第一臨界點為CP1,第二臨界點為CP2,第三臨界點為CP3,第四臨界點為CP4,第五臨界點為CP5,第六臨界點為CP6,關於第二實施例的前述臨界點的種類請參見表五。
<第三實施例><Third embodiment>
第三實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第三實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含一低臨界點。第三實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the third embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the third embodiment, please refer to Figure 1, for the color sample part, please refer to Figure 2A to Figure 3C, and for the light blocking ring, please refer to Figure 4 to Figure 11. The annular region contains a low critical point. The contact lens of the third embodiment can optionally contain a cycloplegic agent.
<第四實施例><Fourth embodiment>
第四實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第四實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含一高臨界點以及一低臨界點。第四實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the fourth embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the fourth embodiment, refer to Fig. 1, for the color sample part, refer to Fig. 2A to Fig. 3C, and for the light blocking ring, refer to Fig. 4 to Fig. 11. The annular region includes a high critical point and a low critical point. The contact lens of the fourth embodiment can optionally contain a cycloplegic agent.
<第五實施例><Fifth Embodiment>
第五實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第五實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含二高臨界點。第五實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the fifth embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. Refer to Fig. 1 for the structure of the contact lens of the fifth embodiment, Fig. 2A to Fig. 3C for the color sample part, and Fig. 4 to Fig. 11 for the light blocking ring. The annular region contains two high critical points. The contact lens of the fifth embodiment can optionally contain a cycloplegic agent.
請同時參照表六以及第14圖,表六列出第五實施例的隱形眼鏡的半徑及其所對應的屈光度,第14圖為第五實施例的隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離)。
第五實施例的隱形眼鏡中,POWC、PPmax、DiC、DiP、PPH、PPM、PPL、PCP1、PCP2、PCP3、PCP4、PCP5、PCP6等參數的數值及相關條件式的數值請參見表七,前述參數的定義請參照第一實施例。
第五實施例的隱形眼鏡中,第一臨界點為CP1,第二臨界點為CP2,第三臨界點為CP3,第四臨界點為CP4,第五臨界點為CP5,第六臨界點為CP6,關於第五實施例的前述臨界點的種類請參見表八。
<第六實施例><Sixth embodiment>
第六實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第六實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含二低臨界點。第六實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the sixth embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the sixth embodiment, refer to Fig. 1, for the color sample part, refer to Fig. 2A to Fig. 3C, and for the light blocking ring, refer to Fig. 4 to Fig. 11. The annular region contains two lower critical points. The contact lens of the sixth embodiment can optionally contain a cycloplegic agent.
請同時參照表九以及第15圖,表九列出第六實施例的隱形眼鏡的半徑及其所對應的屈光度,第15圖為第六實施例的隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離)。
第六實施例的隱形眼鏡中,POWC、PPmax、DiC、DiP、PPH、PPM、PPL、PCP1、PCP2、PCP3、PCP4、PCP5、PCP6等參數的數值及相關條件式的數值請參見表十,前述參數的定義請參照第一實施例。
第六實施例的隱形眼鏡中,第一臨界點為CP1,第二臨界點為CP2,第三臨界點為CP3,第四臨界點為CP4,第五臨界點為CP5,第六臨界點為CP6,關於第六實施例的前述臨界點的種類請參見表十一。
<第七實施例><Seventh embodiment>
第七實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第七實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含二高臨界點、一中臨界點以及一低臨界點。第七實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the seventh embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the seventh embodiment, refer to Fig. 1, for the color sample part, refer to Fig. 2A to Fig. 3C, and for the light blocking ring, refer to Fig. 4 to Fig. 11. The annular area includes two high critical points, a middle critical point and a low critical point. The contact lens of the seventh embodiment can optionally contain a cycloplegic agent.
請同時參照表十二以及第16圖,表十二列出第七實施例的隱形眼鏡的半徑及其所對應的屈光度,第16圖為第七實施例的隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離)。
第七實施例的隱形眼鏡中,POWC、PPmax、DiC、DiP、PPH、PPM、PPL、PCP1、PCP2、PCP3、PCP4、PCP5、PCP6等參數的數值及相關條件式的數值請參見表十三,前述參數的定義請參照第一實施例。
第七實施例的隱形眼鏡中,第一臨界點為CP1,第二臨界點為CP2,第三臨界點為CP3,第四臨界點為CP4,第五臨界點為CP5,第六臨界點為CP6,關於第七實施例的前述臨界點的種類請參見表十四。
<第八實施例><Eighth embodiment>
第八實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第八實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含一高臨界點以及二低臨界點。第八實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the eighth embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. Refer to Fig. 1 for the structure of the contact lens of the eighth embodiment, refer to Fig. 2A to Fig. 3C for the color sample part, and refer to Fig. 4 to Fig. 11 for the light blocking ring. The annular region includes a high critical point and two low critical points. The contact lens of the eighth embodiment can optionally contain a cycloplegic agent.
<第九實施例><Ninth embodiment>
第九實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第九實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含二高臨界點、一中臨界點以及二低臨界點。第九實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the ninth embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. Refer to Fig. 1 for the structure of the contact lens of the ninth embodiment, Fig. 2A to Fig. 3C for the color sample part, and Fig. 4 to Fig. 11 for the light blocking ring. The annular area includes two high critical points, one middle critical point and two low critical points. The contact lens of the ninth embodiment can optionally contain a cycloplegic agent.
請同時參照表十五以及第17圖,表十五列出第九實施例的隱形眼鏡的半徑及其所對應的屈光度,第17圖為第九實施例的隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離)。
第九實施例的隱形眼鏡中,POWC、PPmax、DiC、DiP、PPH、PPM、PPL、PCP1、PCP2、PCP3、PCP4、PCP5、PCP6等參數的數值及相關條件式的數值請參見表十六,前述參數的定義請參照第一實施例。
第九實施例的隱形眼鏡中,第一臨界點為CP1,第二臨界點為CP2,第三臨界點為CP3,第四臨界點為CP4,第五臨界點為CP5,第六臨界點為CP6,關於第九實施例的前述臨界點的種類請參見表十七。
<第十實施例><Tenth Embodiment>
第十實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第十實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含三高臨界點。第十實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the tenth embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the tenth embodiment, refer to Fig. 1, for the color sample part, refer to Fig. 2A to Fig. 3C, and for the light blocking ring, refer to Fig. 4 to Fig. 11. The annular zone contains three high critical points. The contact lens of the tenth embodiment may optionally contain a cycloplegic agent.
請同時參照表十八以及第18圖,表十八列出第十實施例的隱形眼鏡的半徑及其所對應的屈光度,第18圖為第十實施例的隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離)。
第十實施例的隱形眼鏡中,POWC、PPmax、DiC、DiP、PPH、PPM、PPL、PCP1、PCP2、PCP3、PCP4、PCP5、PCP6等參數的數值及相關條件式的數值請參見表十九,前述參數的定義請參照第一實施例。
第十實施例的隱形眼鏡中,第一臨界點為CP1,第二臨界點為CP2,第三臨界點為CP3,第四臨界點為CP4,第五臨界點為CP5,第六臨界點為CP6,關於第十實施例的前述臨界點的種類請參見表二十。
<第十一實施例><Eleventh embodiment>
第十一實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第十一實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含一中臨界點以及三低臨界點。第十一實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the eleventh embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the eleventh embodiment, please refer to Figure 1, for the color sample part, please refer to Figure 2A to Figure 3C, and for the light blocking ring, please refer to Figure 4 to Figure 11. The annular zone includes a middle critical point and three low critical points. The contact lens of the eleventh embodiment can optionally contain a cycloplegic agent.
<第十二實施例><Twelfth embodiment>
第十二實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第十二實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含三高臨界點以及一低臨界點。第十二實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the twelfth embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the twelfth embodiment, please refer to Figure 1, for the color sample part, please refer to Figure 2A to Figure 3C, and for the light blocking ring, please refer to Figure 4 to Figure 11. The annular region contains three high critical points and one low critical point. The contact lens of the twelfth embodiment can optionally contain a cycloplegic agent.
請同時參照表二十一以及第19圖,表二十一列出第十二實施例的隱形眼鏡的半徑及其所對應的屈光度,第19圖為第十二實施例的隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離)。
第十二實施例的隱形眼鏡中,POWC、PPmax、DiC、DiP、PPH、PPM、PPL、PCP1、PCP2、PCP3、PCP4、PCP5、PCP6等參數的數值及相關條件式的數值請參見表二十二,前述參數的定義請參照第一實施例。
第十二實施例的隱形眼鏡中,第一臨界點為CP1,第二臨界點為CP2,第三臨界點為CP3,第四臨界點為CP4,第五臨界點為CP5,第六臨界點為CP6,關於第十二實施例的前述臨界點的種類請參見表二十三。
<第十三實施例><Thirteenth embodiment>
第十三實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第十三實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含一高臨界點以及三低臨界點。第十三實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the thirteenth embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the thirteenth embodiment, please refer to Figure 1, for the color sample part, please refer to Figure 2A to Figure 3C, and for the light blocking ring, please refer to Figure 4 to Figure 11. The annular region includes a high critical point and three low critical points. The contact lens of the thirteenth embodiment can optionally contain a cycloplegic agent.
<第十四實施例><Fourteenth embodiment>
第十四實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第十四實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含三高臨界點、一中臨界點以及二低臨界點。第十四實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the fourteenth embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the fourteenth embodiment, please refer to Figure 1, for the color sample part, please refer to Figure 2A to Figure 3C, and for the light blocking ring, please refer to Figure 4 to Figure 11. The annular zone includes three high critical points, one middle critical point and two low critical points. The contact lens of the fourteenth embodiment can optionally contain a cycloplegic agent.
<第十五實施例><Fifteenth embodiment>
第十五實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第十五實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含二高臨界點以及三低臨界點。第十五實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the fifteenth embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the fifteenth embodiment, please refer to Figure 1, for the color sample part, please refer to Figure 2A to Figure 3C, and for the light blocking ring, please refer to Figure 4 to Figure 11. The annular region contains two high critical points and three low critical points. The contact lens of the fifteenth embodiment can optionally contain a cycloplegic agent.
<第十六實施例><Sixteenth embodiment>
第十六實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第十六實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含三高臨界點以及三低臨界點。第十六實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the sixteenth embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the sixteenth embodiment, please refer to Figure 1, for the color sample part, please refer to Figure 2A to Figure 3C, and for the light blocking ring, please refer to Figure 4 to Figure 11. The annular region contains three high critical points and three low critical points. The contact lens of the sixteenth embodiment can optionally contain a cycloplegic agent.
請同時參照表二十四以及第20圖,表二十四列出第十六實施例的隱形眼鏡的半徑及其所對應的屈光度,第20圖為第十六實施例的隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離)。
第十六實施例的隱形眼鏡中,POWC、PPmax、DiC、DiP、PPH、PPM、PPL、PCP1、PCP2、PCP3、PCP4、PCP5、PCP6等參數的數值及相關條件式的數值請參見表二十五,前述參數的定義請參照第一實施例。
第十六實施例的隱形眼鏡中,第一臨界點為CP1,第二臨界點為CP2,第三臨界點為CP3,第四臨界點為CP4,第五臨界點為CP5,第六臨界點為CP6,關於第十六實施例的前述臨界點的種類請參見表二十六。
<第十七實施例><Seventeenth embodiment>
第十七實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第十七實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含四高臨界點以及一中臨界點。第十七實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the seventeenth embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the seventeenth embodiment, please refer to Figure 1, for the color sample part, please refer to Figure 2A to Figure 3C, and for the light blocking ring, please refer to Figure 4 to Figure 11. The annular zone contains four high critical points and one middle critical point. The contact lens of the seventeenth embodiment can optionally contain a cycloplegic agent.
<第十八實施例><Eighteenth embodiment>
第十八實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第十八實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含四低臨界點。第十八實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the eighteenth embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the eighteenth embodiment, please refer to Figure 1, for the color sample part, please refer to Figure 2A to Figure 3C, and for the light blocking ring, please refer to Figure 4 to Figure 11. The annular region contains four low critical points. The contact lens of the eighteenth embodiment can optionally contain a cycloplegic agent.
<第十九實施例><Nineteenth embodiment>
第十九實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第十九實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含四高臨界點、二中臨界點以及一低臨界點。第十九實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the nineteenth embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the nineteenth embodiment, please refer to Figure 1, for the color sample part, please refer to Figures 2A to 3C, and for the light blocking ring, please refer to Figures 4 to 11. The annular area includes four high critical points, two middle critical points and one low critical point. The contact lens of the nineteenth embodiment can optionally contain a cycloplegic agent.
<第二十實施例><Twentieth Embodiment>
第二十實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第二十實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含一高臨界點、一中臨界點以及四低臨界點。第二十實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the twentieth embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the twentieth embodiment, please refer to Figure 1, for the color sample part, please refer to Figures 2A to 3C, and for the light blocking ring, please refer to Figures 4 to 11. The annular area includes a high critical point, a middle critical point and four low critical points. The contact lens of the twentieth embodiment can optionally contain a cycloplegic agent.
<第二十一實施例><Twenty-first embodiment>
第二十一實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第二十一實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含四高臨界點以及二低臨界點。第二十一實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the twenty-first embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the twenty-first embodiment, please refer to Figure 1, for the color sample part, please refer to Figure 2A to Figure 3C, and for the light blocking ring, please refer to Figure 4 to Figure 11. The annular region contains four high critical points and two low critical points. The contact lens of the twenty-first embodiment can optionally contain a cycloplegic agent.
請同時參照表二十七以及第21圖,表二十七列出第二十一實施例的隱形眼鏡的半徑及其所對應的屈光度,第21圖為第二十一實施例的隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離)。
第二十一實施例的隱形眼鏡中,POWC、PPmax、DiC、DiP、PPH、PPM、PPL、PCP1、PCP2、PCP3、PCP4、PCP5、PCP6等參數的數值及相關條件式的數值請參見表二十八,前述參數的定義請參照第一實施例。
第二十一實施例的隱形眼鏡中,第一臨界點為CP1,第二臨界點為CP2,第三臨界點為CP3,第四臨界點為CP4,第五臨界點為CP5,第六臨界點為CP6,關於第二十一實施例的前述臨界點的種類請參見表二十九。
<第二十二實施例><Twenty-second embodiment>
第二十二實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第二十二實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含二高臨界點、一中臨界點以及四低臨界點。第二十二實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the twenty-second embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the twenty-second embodiment, please refer to Figure 1, for the color sample part, please refer to Figure 2A to Figure 3C, and for the light blocking ring, please refer to Figure 4 to Figure 11. The annular area includes two high critical points, one middle critical point and four low critical points. The contact lens of the twenty-second embodiment can optionally contain a cycloplegic agent.
<第二十三實施例><Twenty-third embodiment>
第二十三實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第二十三實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含四高臨界點、三中臨界點以及三低臨界點。第二十三實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the twenty-third embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the twenty-third embodiment, please refer to Figure 1, for the color sample part, please refer to Figures 2A to 3C, and for the light blocking ring, please refer to Figures 4 to 11. The annular zone contains four high critical points, three middle critical points and three low critical points. The contact lens of the twenty-third embodiment can optionally contain a cycloplegic agent.
<第二十四實施例><Twenty-fourth embodiment>
第二十四實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第二十四實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含三高臨界點、一中臨界點以及四低臨界點。第二十四實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the twenty-fourth embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the twenty-fourth embodiment, please refer to Figure 1, for the color sample part, please refer to Figure 2A to Figure 3C, and for the light blocking ring, please refer to Figure 4 to Figure 11. The annular zone contains three high critical points, one middle critical point and four low critical points. The contact lens of the twenty-fourth embodiment can optionally contain a cycloplegic agent.
<第二十五實施例><The twenty-fifth embodiment>
第二十五實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第二十五實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含四高臨界點、二中臨界點以及四低臨界點。第二十五實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the twenty-fifth embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the twenty-fifth embodiment, please refer to Figure 1, for the color sample part, please refer to Figure 2A to Figure 3C, and for the light blocking ring, please refer to Figure 4 to Figure 11. The annular zone contains four high critical points, two middle critical points and four low critical points. The contact lens of the twenty-fifth embodiment can optionally contain a cycloplegic agent.
<第二十六實施例><Twenty-sixth embodiment>
第二十六實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第二十六實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含二高臨界點以及一低臨界點。第二十六實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the twenty-sixth embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the twenty-sixth embodiment, please refer to Figure 1, for the color sample part, please refer to Figures 2A to 3C, and for the light blocking ring, please refer to Figures 4 to 11. The annular region includes two high critical points and a low critical point. The contact lens of the twenty-sixth embodiment can optionally contain a cycloplegic agent.
請同時參照表三十以及第22圖,表三十列出第二十六實施例的隱形眼鏡的半徑及其所對應的屈光度,第22圖為第二十六實施例的隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離)。
第二十六實施例的隱形眼鏡中,POWC、PPmax、DiC、DiP、PPH、PPM、PPL、PCP1、PCP2、PCP3、PCP4、PCP5、PCP6等參數的數值及相關條件式的數值請參見表三十一,前述參數的定義請參照第一實施例。
第二十六實施例的隱形眼鏡中,第一臨界點為CP1,第二臨界點為CP2,第三臨界點為CP3,第四臨界點為CP4,第五臨界點為CP5,第六臨界點為CP6,關於第二十六實施例的前述臨界點的種類請參見表三十二。
<第二十七實施例><Twenty-seventh embodiment>
第二十七實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第二十七實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含二高臨界點以及一低臨界點。第二十七實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the twenty-seventh embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the twenty-seventh embodiment, please refer to Figure 1, for the color sample part, please refer to Figures 2A to 3C, and for the light blocking ring, please refer to Figures 4 to 11. The annular region includes two high critical points and a low critical point. The contact lens of the twenty-seventh embodiment can optionally contain a cycloplegic agent.
請同時參照表三十三以及第23圖,表三十三列出第二十七實施例的隱形眼鏡的半徑及其所對應的屈光度,第23圖為第二十七實施例的隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離)。
第二十七實施例的隱形眼鏡中,POWC、PPmax、DiC、DiP、PPH、PPM、PPL、PCP1、PCP2、PCP3、PCP4、PCP5、PCP6等參數的數值及相關條件式的數值請參見表三十四,前述參數的定義請參照第一實施例。
第二十七實施例的隱形眼鏡中,第一臨界點為CP1,第二臨界點為CP2,第三臨界點為CP3,第四臨界點為CP4,第五臨界點為CP5,第六臨界點為CP6,關於第二十七實施例的前述臨界點的種類請參見表三十五。
<第二十八實施例><Twenty-eighth embodiment>
第二十八實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第二十八實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含二高臨界點以及一低臨界點。第二十八實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the twenty-eighth embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the twenty-eighth embodiment, please refer to Figure 1, for the color sample part, please refer to Figures 2A to 3C, and for the light blocking ring, please refer to Figures 4 to 11. The annular region includes two high critical points and a low critical point. The contact lens of the twenty-eighth embodiment can optionally contain a cycloplegic agent.
請同時參照表三十六以及第24圖,表三十六列出第二十八實施例的隱形眼鏡的半徑及其所對應的屈光度,第24圖為第二十八實施例的隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離)。
第二十八實施例的隱形眼鏡中,POWC、PPmax、DiC、DiP、PPH、PPM、PPL、PCP1、PCP2、PCP3、PCP4、PCP5、PCP6等參數的數值及相關條件式的數值請參見表三十七,前述參數的定義請參照第一實施例。
第二十八實施例的隱形眼鏡中,第一臨界點為CP1,第二臨界點為CP2,第三臨界點為CP3,第四臨界點為CP4,第五臨界點為CP5,第六臨界點為CP6,關於第二十八實施例的前述臨界點的種類請參見表三十八。
<第二十九實施例><Twenty-ninth embodiment>
第二十九實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第二十九實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含二高臨界點以及一低臨界點。第二十九實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the twenty-ninth embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the twenty-ninth embodiment, please refer to Figure 1, for the color sample part, please refer to Figures 2A to 3C, and for the light blocking ring, please refer to Figures 4 to 11. The annular region includes two high critical points and a low critical point. The contact lens of the twenty-ninth embodiment can optionally contain a cycloplegic agent.
請同時參照表三十九以及第25圖,表三十九列出第二十九實施例的隱形眼鏡的半徑及其所對應的屈光度,第25圖為第二十九實施例的隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離)。
第二十九實施例的隱形眼鏡中,POWC、PPmax、DiC、DiP、PPH、PPM、PPL、PCP1、PCP2、PCP3、PCP4、PCP5、PCP6等參數的數值及相關條件式的數值請參見表四十,前述參數的定義請參照第一實施例。
第二十九實施例的隱形眼鏡中,第一臨界點為CP1,第二臨界點為CP2,第三臨界點為CP3,第四臨界點為CP4,第五臨界點為CP5,第六臨界點為CP6,關於第二十九實施例的前述臨界點的種類請參見表四十一。
<第三十實施例><Thirtieth embodiment>
第三十實施例的隱形眼鏡包含一中心區、一環形區以及一周邊區。中心區包含隱形眼鏡的中心點,環形區對稱環繞中心區,周邊區對稱環繞環形區。周邊區可包含至少一色樣部。中心區外可包含至少一阻光環。關於第三十實施例隱形眼鏡的結構可參照第1圖,關於色樣部可參照第2A圖至第3C圖,關於阻光環可參照第4圖至第11圖。環形區包含二高臨界點以及一中臨界點。第三十實施例的隱形眼鏡可視需求包含睫狀肌麻痺劑。The contact lens of the thirtieth embodiment includes a central zone, an annular zone, and a peripheral zone. The central zone contains the central point of the contact lens, the annular zone symmetrically surrounds the central zone, and the peripheral zone symmetrically surrounds the annular zone. The peripheral area can include at least one color sample. At least one light-blocking ring can be included outside the central area. For the structure of the contact lens of the thirtieth embodiment, refer to Fig. 1, for the color sample part, refer to Fig. 2A to Fig. 3C, and for the light blocking ring, refer to Fig. 4 to Fig. 11. The annular area includes two high critical points and a middle critical point. The contact lens of the thirtieth embodiment can optionally contain a cycloplegic agent.
請同時參照表四十二以及第26圖,表四十二列出第三十實施例的隱形眼鏡的半徑及其所對應的屈光度,第26圖為第三十實施例的隱形眼鏡的半徑與屈光度的關係圖(負值僅示意為相反方向半徑距離)。
第三十實施例的隱形眼鏡中,POWC、PPmax、DiC、DiP、PPH、PPM、PPL、PCP1、PCP2、PCP3、PCP4、PCP5、PCP6等參數的數值及相關條件式的數值請參見表四十三,前述參數的定義請參照第一實施例。
第三十實施例的隱形眼鏡中,第一臨界點為CP1,第二臨界點為CP2,第三臨界點為CP3,第四臨界點為CP4,第五臨界點為CP5,第六臨界點為CP6,關於第三十實施例的前述臨界點的種類請參見表四十四。
由上述實施例可知,本發明的隱形眼鏡藉由包含至少一臨界點,可藉由分段式提升離焦程度與漸進式緩和離焦程度,可有效緩和離開中心區的屈光度提升幅度,提升配戴的舒適性,而有助提升長周期的治療可能性。It can be seen from the above-mentioned embodiments that the contact lens of the present invention can effectively alleviate the degree of diopter increase away from the central area by segmentally increasing the degree of defocus and gradually relieving the degree of defocus by including at least one critical point, thereby improving the degree of defocus. It improves the comfort of wearing and helps to improve the possibility of long-term treatment.
依據本發明的隱形眼鏡,中心區具有使配戴者中央視野能夠清楚對焦的功能,但也可視情況較配戴者近視度數減少0.25 D~0.50 D以減緩配戴不適感。中心區包含隱形眼鏡的中心點,且屈光度恆定。According to the contact lens of the present invention, the central area has the function of enabling the wearer's central vision to focus clearly, but it can also reduce the wearer's myopia by 0.25 D~0.50 D depending on the situation, so as to alleviate wearing discomfort. The central zone contains the center point of the contact lens and has a constant diopter.
依據本發明的隱形眼鏡,環形區可預防近視或控制近視。環形區直徑最大可至8 mm。環形區可設置至少一阻光環或色樣部(由周邊區延伸至環形區)。According to the contact lens of the present invention, the annular zone can prevent myopia or control myopia. The diameter of the annular zone can be up to 8 mm. The annular area can be provided with at least one light-blocking ring or color sample (extending from the peripheral area to the annular area).
依據本發明的隱形眼鏡,周邊區可使隱形眼鏡貼附眼球並具支撐功能。周邊區可設置至少一色樣部或至少一阻光環(由環形區延伸至周邊區)。周邊區為直徑大於8 mm以外的環形區域。According to the contact lens of the present invention, the peripheral region can make the contact lens adhere to the eyeball and have a supporting function. The peripheral area can be provided with at least one color sample portion or at least one light blocking ring (extending from the ring area to the peripheral area). The peripheral zone is an annular area with a diameter greater than 8 mm.
依據本發明的隱形眼鏡,色樣部主要設置於周邊區,可延伸至環形區(即環形區佔部分),通常具有不規則圖樣,可為但不限輻射狀、花瓣狀或圓環狀。每一色樣部具有一種顏色,顏色可選自紅、橙、黃、綠、藍、靛、紫、黑、白、銀或金色。當色樣部為黑色時,其最大外直徑大於12.0 mm。若以隱形眼鏡的中心點為中心,將隱形眼鏡水平垂直切分為ABCD四象限區,其中可至少兩象限區具有重複圖樣以形成對稱,可有助於達成不同象限但具一致減少雜散光效果,當四象限區中的重複圖樣越多,減少雜散光的一致性越佳。色樣部可設計為正反辨識的圖樣,有助於提供使用者正確配戴方向的功能性。According to the contact lens of the present invention, the color sample part is mainly arranged in the peripheral area, and can extend to the annular area (that is, the annular area occupies a part), and usually has an irregular pattern, which can be but not limited to radial, petal, or circular. Each color sample part has a color, and the color can be selected from red, orange, yellow, green, blue, indigo, purple, black, white, silver or gold. When the color sample part is black, its maximum outer diameter is greater than 12.0 mm. If the center point of the contact lens is used as the center, the contact lens is divided horizontally and vertically into four quadrants of ABCD, and at least two of the quadrants can have repeated patterns to form symmetry, which can help achieve different quadrants but have a consistent effect of reducing stray light , when there are more repeated patterns in the four-quadrant area, the consistency of reducing stray light is better. The color sample part can be designed as a positive and negative identification pattern, which helps to provide the user with the functionality of correct wearing direction.
依據本發明的隱形眼鏡,阻光環設置於中心區以外的區域,具體來說,阻光環主要設置於環形區,可延伸至周邊區(即周邊區佔部分)。阻光環通常分布均勻,可為單色、點狀分布、單圓環、多圓環等。阻光環的顏色可選自紅、橙、黃、綠、藍、靛、紫、黑、白、銀或金色。According to the contact lens of the present invention, the light-blocking ring is disposed in an area other than the central area, specifically, the light-blocking ring is mainly disposed in the annular area, and can extend to the peripheral area (that is, the peripheral area occupies a part). The light-blocking rings are usually evenly distributed, and can be monochrome, dot-shaped, single-ring, multi-ring, etc. The color of the light blocking ring can be selected from red, orange, yellow, green, blue, indigo, purple, black, white, silver or gold.
依據本發明的隱形眼鏡,阻光環的最小可見光平均穿透率小於50%;或者,阻光環的最小可見光平均穿透率小於40%;或者,阻光環的最小可見光平均穿透率小於30%;或者,阻光環的最小可見光平均穿透率小於15%。前述最小可見光平均穿透率測定方式如下:選取阻光環上任何一點進行可見光平均穿透率測定(範圍400nm~700nm),阻光環區域中所能測得具有最低穿透率者,即可作為代表阻光環最小可見光平均穿透率,一般而言,黑色阻光環最小可見光平均穿透率小於10%,半透明阻光環最小可見光平均透光率小於50%。According to the contact lens of the present invention, the minimum average visible light transmittance of the light-blocking ring is less than 50%; or, the minimum visible light average transmittance of the light-blocking ring is less than 40%; or, the minimum visible light average transmittance of the light-blocking ring is less than 30%; Alternatively, the minimum visible light average transmittance of the light-blocking ring is less than 15%. The above-mentioned minimum visible light average transmittance measurement method is as follows: select any point on the light-blocking ring to measure the visible light average transmittance (range 400nm~700nm), and the one with the lowest transmittance that can be measured in the light-blocking ring area can be used as a representative The minimum visible light average transmittance of the light-blocking ring. Generally speaking, the minimum visible light average transmittance of the black light-blocking ring is less than 10%, and the minimum visible light average transmittance of the translucent light-blocking ring is less than 50%.
依據本發明的隱形眼鏡,臨界點是指在半徑與屈光度關係圖中切線斜率為0的點,亦即其切線垂直Y軸(D值),其中最靠近臨界點的左右兩點的D值必同時大於或小於臨界點值。臨界點數量的計算係以隱形眼鏡的中心點朝外至隱形眼鏡周邊任取一條半徑線段,繪製該半徑線段上的半徑與屈光度關係圖,計算該半徑線段的環形區具有的臨界點數量,該些臨界點可能包含高臨界點、中臨界點與低臨界點。此外,相同D值的臨界點值僅計算一次。According to the contact lens of the present invention, the critical point refers to the point where the slope of the tangent line in the relationship between radius and diopter is 0, that is, the tangent line is perpendicular to the Y axis (D value), wherein the D values of the two points on the left and right closest to the critical point must be Both greater and less than the critical point value. The calculation of the number of critical points is to take a radius line segment from the center point of the contact lens outward to the periphery of the contact lens, draw the relationship between the radius and the diopter on the radius line segment, and calculate the number of critical points in the annular area of the radius line segment. These critical points may include high critical point, middle critical point and low critical point. Also, the critical point value for the same D value is calculated only once.
依據本發明的隱形眼鏡,D值係指屈光度的大小。According to the contact lens of the present invention, the D value refers to the diopter.
依據本發明的隱形眼鏡,臨界點的命名係依照由中心朝向周邊的順序,最接近中心的臨界點為第一臨界點(Critical Point 1,CP1),之後往周邊方向依序為第二臨界點、第三臨界點,依此類推。According to the contact lens of the present invention, the critical points are named according to the order from the center to the periphery, the critical point closest to the center is the first critical point (Critical Point 1, CP1), and then the second critical point in the direction of the periphery , the third critical point, and so on.
依據本發明的隱形眼鏡,第一臨界點值(Power of Critical Point 1,PCP1)為第一臨界點的屈光度,第二臨界點值(PCP2)為第二臨界點的屈光度,依此類推。According to the contact lens of the present invention, the first critical point value (PCP1) is the diopter of the first critical point, the second critical point value (PCP2) is the diopter of the second critical point, and so on.
依據本發明的隱形眼鏡,隱形眼鏡可為透明片,其可見光平均穿透率大於92%;或者,隱形眼鏡可添加藍染料,其可見光平均穿透率大於83%;或者,隱形眼鏡可添加紫外光吸收劑(UV absorber),其可見光平均穿透率大於91%;或者,隱形眼鏡可添加藍光吸收劑(blue blocker),其可見光平均穿透率大於75%。According to the contact lens of the present invention, the contact lens can be a transparent sheet, and its average visible light transmittance is greater than 92%; or, the contact lens can be added with blue dye, and its visible light average transmittance is greater than 83%; or, the contact lens can be added with ultraviolet rays. A light absorber (UV absorber), whose average visible light transmittance is greater than 91%; or, a blue light absorber (blue blocker), whose visible light average transmittance is greater than 75%, can be added to the contact lens.
本發明中的睫狀肌麻痺劑包含但不限於阿托品(Atropine;(3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl tropate)、托吡卡胺(Tropicamide;N-Ethyl-3-hydroxy-2-phenyl-N-(4-pyridinylmethyl)propanamide)、環戊醇胺酯(Cyclopentolate;2-(Dimethylamino)ethyl (1-hydroxycyclopentyl)(phenyl)acetate)、后馬托品(Homatropine;(3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl hydroxy(phenyl)acetate)、東莨菪鹼(Scopolamine ;(1R,2R,4S,5S,7s)-9-Methyl-3-oxa-9-azatricyclo[3.3.1.02,4 ]non-7-yl(2S)-3-hydroxy-2-phenylpropanoate)與尤卡托品(Eucatropine;1,2,2,6-Tetramethyl-4-piperidinyl hydroxy(phenyl)acetate)及前述物質的鹽類。睫狀肌麻痺劑又稱為作散瞳劑,並屬於副交感神經阻斷劑,亦即為一種非選擇性的M型蕈毒鹼受器阻斷藥,其可藉由阻斷蕈毒鹼受器而使控制瞳孔的睫狀肌麻痺與鬆弛,進而使得瞳孔放大。Cycloplegic agents in the present invention include but are not limited to atropine (Atropine; (3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl tropate), tropicamide (Tropicamide; N-Ethyl-3-hydroxy-2-phenyl-N-(4-pyridinylmethyl)propanamide), cyclopentolamine ester (Cyclopentolate; 2-(Dimethylamino)ethyl (1-hydroxycyclopentyl)(phenyl)acetate), homatolate Products (Homatropine; (3-endo)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl hydroxy(phenyl)acetate), Scopolamine (Scopolamine; (1R,2R,4S,5S,7s)- 9-Methyl-3-oxa-9-azatricyclo[3.3.1.0 2,4 ]non-7-yl(2S)-3-hydroxy-2-phenylpropanoate) and Eucatropine (Eucatropine; 1,2,2, 6-Tetramethyl-4-piperidinyl hydroxy(phenyl) acetate) and salts of the aforementioned substances. Cycloplegics, also known as mydriatics, belong to parasympathetic blockers, that is, a non-selective M-type muscarinic receptor blocker, which can block muscarinic receptors Paralyzes and relaxes the cyclone muscles that control the pupils, causing the pupils to dilate.
雖然本發明已以實施方式揭露如上,然其並非用以限定本發明,任何熟習此技藝者,在不脫離本發明的精神和範圍內,當可作各種的更動與潤飾,因此本發明的保護範圍當視後附的申請專利範圍所界定者為準。Although the present invention has been disclosed above in terms of implementation, it is not intended to limit the present invention. Anyone skilled in the art can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the protection of the present invention The scope shall be defined by the scope of the appended patent application.
10,100,200,300,400,500,600,700,800,900,1000,1100:隱形眼鏡 20:浸潤溶液 30:隱形眼鏡產品 110,210,310:中心區 120,220,320:環形區 130,230,330:周邊區 240A,340A:第一色樣部 240B,340B:第二色樣部 450,550,650,750,850,950,1050,1150:阻光環 O:中心點 POWC:中心區的屈光度 PPmax:環形區的最大屈光度 PPH:高臨界點值 PPM:中臨界點值 PPL:低臨界點值 DiC:中心區的最大直徑 DiP:環形區的最大直徑 CP1:第一臨界點 CP2:第二臨界點 CP3:第三臨界點 CP4:第四臨界點 CP5:第五臨界點 CP6:第六臨界點 PCP1:第一臨界點值 PCP2:第二臨界點值 PCP3:第三臨界點值 PCP4:第四臨界點值 PCP5:第五臨界點值 PCP6:第六臨界點值 CH:高臨界點 CM:中臨界點 CL:低臨界點 DBi:阻光環的最小內直徑 DBo:阻光環的最大外直徑 Do:隱形眼鏡的最大外徑 ConA:睫狀肌麻痺劑於隱形眼鏡或於浸潤溶液中的重量百分比濃度10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100: contact lenses 20: Infiltration solution 30:Contact lens products 110,210,310: central area 120,220,320: ring area 130,230,330: Surrounding area 240A, 340A: the first color sample department 240B, 340B: the second color sample department 450,550,650,750,850,950,1050,1150: blocking halo O: center point POWC: Diopter in the central area PPmax: the maximum diopter of the annular area PPH: High Threshold Value PPM: middle critical point value PPL: Low critical point value DiC: the largest diameter of the central zone DiP: Maximum diameter of the annular zone CP1: first critical point CP2: Second critical point CP3: The third critical point CP4: The fourth critical point CP5: Fifth critical point CP6: Sixth critical point PCP1: first critical point value PCP2: second critical point value PCP3: third critical point value PCP4: Fourth critical point value PCP5: fifth critical point value PCP6: Sixth critical point value CH: high critical point CM: Midpoint CL: low critical point DBi: the minimum inner diameter of the light blocking ring DBo: the maximum outer diameter of the light blocking ring Do: the maximum outer diameter of the contact lens ConA: concentration by weight of cycloplegic agent in contact lens or in infiltration solution
第1圖繪示依照本發明第一實施方式的一種隱形眼鏡的分區示意圖; 第2A圖繪示依照本發明第二實施方式的一種隱形眼鏡的分區示意圖; 第2B圖繪示第2A圖中隱形眼鏡的側視圖; 第2C圖繪示第2A圖中隱形眼鏡的俯視圖; 第3A圖繪示依照本發明第三實施方式的一種隱形眼鏡的分區示意圖; 第3B圖繪示第3A圖中隱形眼鏡的側視圖; 第3C圖繪示第3A圖中隱形眼鏡的俯視圖; 第4圖繪示依照本發明第四實施方式的一種隱形眼鏡的阻光環配置示意圖; 第5圖繪示依照本發明第五實施方式的一種隱形眼鏡的阻光環配置示意圖; 第6圖繪示依照本發明第六實施方式的一種隱形眼鏡的阻光環配置示意圖; 第7圖繪示依照本發明第七實施方式的一種隱形眼鏡的阻光環配置示意圖; 第8圖繪示依照本發明第八實施方式的一種隱形眼鏡的阻光環配置示意圖; 第9圖繪示依照本發明第九實施方式的一種隱形眼鏡的阻光環配置示意圖; 第10圖繪示依照本發明第十實施方式的一種隱形眼鏡的阻光環配置示意圖; 第11圖繪示依照本發明第十一實施方式的一種隱形眼鏡的阻光環配置示意圖; 第12圖為第一實施例的隱形眼鏡的半徑與屈光度的關係圖; 第13圖為第二實施例的隱形眼鏡的半徑與屈光度的關係圖; 第14圖為第五實施例的隱形眼鏡的半徑與屈光度的關係圖; 第15圖為第六實施例的隱形眼鏡的半徑與屈光度的關係圖; 第16圖為第七實施例的隱形眼鏡的半徑與屈光度的關係圖; 第17圖為第九實施例的隱形眼鏡的半徑與屈光度的關係圖; 第18圖為第十實施例的隱形眼鏡的半徑與屈光度的關係圖; 第19圖為第十二實施例的隱形眼鏡的半徑與屈光度的關係圖; 第20圖為第十六實施例的隱形眼鏡的半徑與屈光度的關係圖; 第21圖為第二十一實施例的隱形眼鏡的半徑與屈光度的關係圖; 第22圖為第二十六實施例的隱形眼鏡的半徑與屈光度的關係圖; 第23圖為第二十七實施例的隱形眼鏡的半徑與屈光度的關係圖; 第24圖為第二十八實施例的隱形眼鏡的半徑與屈光度的關係圖; 第25圖為第二十九實施例的隱形眼鏡的半徑與屈光度的關係圖; 第26圖為第三十實施例的隱形眼鏡的半徑與屈光度的關係圖;以及 第27圖繪示依照本發明第十二實施方式的一種隱形眼鏡產品的示意圖。FIG. 1 shows a schematic partition diagram of a contact lens according to the first embodiment of the present invention; FIG. 2A shows a schematic partition diagram of a contact lens according to the second embodiment of the present invention; Figure 2B shows a side view of the contact lens in Figure 2A; Figure 2C shows a top view of the contact lens in Figure 2A; FIG. 3A shows a schematic partition diagram of a contact lens according to a third embodiment of the present invention; Figure 3B shows a side view of the contact lens in Figure 3A; Figure 3C shows a top view of the contact lens in Figure 3A; FIG. 4 shows a schematic diagram of a configuration of a light-blocking ring of a contact lens according to a fourth embodiment of the present invention; FIG. 5 shows a schematic diagram of a configuration of a light-blocking ring of a contact lens according to a fifth embodiment of the present invention; FIG. 6 shows a schematic diagram of a configuration of a light-blocking ring of a contact lens according to a sixth embodiment of the present invention; FIG. 7 shows a schematic diagram of a configuration of a light-blocking ring of a contact lens according to a seventh embodiment of the present invention; FIG. 8 shows a schematic diagram of a configuration of a light-blocking ring of a contact lens according to an eighth embodiment of the present invention; FIG. 9 shows a schematic diagram of a configuration of a light-blocking ring of a contact lens according to a ninth embodiment of the present invention; FIG. 10 shows a schematic diagram of a configuration of a light-blocking ring of a contact lens according to a tenth embodiment of the present invention; FIG. 11 shows a schematic diagram of a configuration of a light-blocking ring of a contact lens according to an eleventh embodiment of the present invention; Fig. 12 is a relationship diagram between the radius and the diopter of the contact lens of the first embodiment; Fig. 13 is a relation diagram between the radius and the diopter of the contact lens of the second embodiment; The 14th figure is the relation diagram of the radius and diopter of the contact lens of the fifth embodiment; Fig. 15 is a relational diagram of the radius and diopter of the contact lens of the sixth embodiment; The 16th figure is the relationship diagram of the radius and diopter of the contact lens of the seventh embodiment; The 17th figure is the relation diagram of the radius and the diopter of the contact lens of the ninth embodiment; Fig. 18 is a relational diagram of the radius and diopter of the contact lens of the tenth embodiment; Fig. 19 is a relationship diagram between the radius and the diopter of the contact lens of the twelfth embodiment; Fig. 20 is a relationship diagram between the radius and the diopter of the contact lens of the sixteenth embodiment; Fig. 21 is a relation diagram between the radius and diopter of the contact lens of the twenty-first embodiment; Fig. 22 is a relation diagram between the radius and diopter of the contact lens of the twenty-sixth embodiment; Fig. 23 is a relation diagram between the radius and diopter of the contact lens of the twenty-seventh embodiment; Figure 24 is a relationship diagram between the radius and the diopter of the contact lens of the twenty-eighth embodiment; Fig. 25 is a relation diagram between the radius and diopter of the contact lens of the twenty-ninth embodiment; Fig. 26 is a relationship diagram between the radius and diopter of the contact lens of the thirtieth embodiment; and Fig. 27 is a schematic diagram of a contact lens product according to the twelfth embodiment of the present invention.
100:隱形眼鏡 100: contact lenses
110:中心區 110: Central area
120:環形區 120: ring area
130:周邊區 130: Surrounding area
O:中心點 O: center point
DiC:中心區的最大直徑 DiC: the maximum diameter of the central zone
DiP:環形區的最大直徑 DiP: Maximum diameter of the annular zone
Claims (11)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762523815P | 2017-06-23 | 2017-06-23 | |
US62/523,815 | 2017-06-23 | ||
TW106122920 | 2017-07-07 | ||
TW106122920 | 2017-07-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW202208947A TW202208947A (en) | 2022-03-01 |
TWI788094B true TWI788094B (en) | 2022-12-21 |
Family
ID=80784505
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW111144544A TW202309582A (en) | 2017-06-23 | 2017-08-24 | Contact lens and product thereof |
TW109124331A TWI749646B (en) | 2017-06-23 | 2017-08-24 | Contact lens and product thereof |
TW110141914A TWI788094B (en) | 2017-06-23 | 2017-08-24 | Contact lens and product thereof |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW111144544A TW202309582A (en) | 2017-06-23 | 2017-08-24 | Contact lens and product thereof |
TW109124331A TWI749646B (en) | 2017-06-23 | 2017-08-24 | Contact lens and product thereof |
Country Status (1)
Country | Link |
---|---|
TW (3) | TW202309582A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015514233A (en) * | 2012-04-05 | 2015-05-18 | ブリエン ホールデン ビジョン インスティテュートBrien Holden Vision Institute | Refractive anomaly lens, device, method and system |
TW201610507A (en) * | 2008-03-31 | 2016-03-16 | 壯生和壯生視覺關懷公司 | Lenses for the correction of presbyopia and methods of designing the lenses |
US20170075138A1 (en) * | 2015-09-15 | 2017-03-16 | Largan Medical Co., Ltd. | Contact lens product |
CN106526888A (en) * | 2015-09-15 | 2017-03-22 | 星欧光学股份有限公司 | Contact lens product |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1518140B1 (en) * | 2002-05-31 | 2011-09-14 | Crossbows Optical Limited | Progressive addition power lens |
US9733494B2 (en) * | 2014-08-29 | 2017-08-15 | Johnson & Johnson Vision Care, Inc. | Free form lens design and method for preventing and/or slowing myopia progression |
-
2017
- 2017-08-24 TW TW111144544A patent/TW202309582A/en unknown
- 2017-08-24 TW TW109124331A patent/TWI749646B/en active
- 2017-08-24 TW TW110141914A patent/TWI788094B/en active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201610507A (en) * | 2008-03-31 | 2016-03-16 | 壯生和壯生視覺關懷公司 | Lenses for the correction of presbyopia and methods of designing the lenses |
JP2015514233A (en) * | 2012-04-05 | 2015-05-18 | ブリエン ホールデン ビジョン インスティテュートBrien Holden Vision Institute | Refractive anomaly lens, device, method and system |
US20170075138A1 (en) * | 2015-09-15 | 2017-03-16 | Largan Medical Co., Ltd. | Contact lens product |
CN106526888A (en) * | 2015-09-15 | 2017-03-22 | 星欧光学股份有限公司 | Contact lens product |
Also Published As
Publication number | Publication date |
---|---|
TW202045988A (en) | 2020-12-16 |
TW202309582A (en) | 2023-03-01 |
TWI749646B (en) | 2021-12-11 |
TW202208947A (en) | 2022-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11867985B2 (en) | Contact lens and product thereof | |
JP7271757B2 (en) | ophthalmic lens | |
AU2017202382B2 (en) | Asymmetric lens design and method for preventing and/or slowing myopia progression | |
KR102573936B1 (en) | Contact lens comprising non-coaxial lenslets for preventing and/or slowing myopia progression | |
KR102453441B1 (en) | Pupil size-independent lens design and method for preventing and/or slowing myopia progression | |
US20200218086A1 (en) | Contact lens with improved, multiple and integrated effects | |
KR20180071177A (en) | High plus center treatment zone lens design and method for preventing and/or slowing myopia progression | |
TWI641892B (en) | Contact lens and contact lens product | |
AU2015201373A1 (en) | Contact lens with pearlescent sclera | |
TWI696862B (en) | Contact lens and contact lens product | |
TWI788094B (en) | Contact lens and product thereof | |
TWI702439B (en) | Contact lens and product thereof | |
TW201426086A (en) | Contact lens adopting chromatic aberration to control myopia with cosmetic effects | |
TWI653488B (en) | Contact lens and product thereof | |
CN109116576A (en) | Contact lenses and products thereof | |
TW201918750A (en) | Filtering region structure of lens including a central optical region and a peripheral optical region | |
TWI740504B (en) | Contact lens and contact lens product | |
TW202144867A (en) | Contact lens and contact lens product |